Phenylephrine hydrochloride

What it is

Phenylephrine hydrochloride is a manufactured salt of phenylephrine. The prescription injection label calls it an alpha-1 adrenergic receptor agonist, meaning it stimulates those receptors directly. Swallowed as a tablet it is the active ingredient in a large number of over-the-counter cold, sinus and allergy products, either alone at 10 mg or alongside paracetamol, ibuprofen, guaifenesin or a cough suppressant. The same substance is also given as a nasal spray, in the eye and by injection in hospital, which are separate routes with separate labels and separate evidence. Taken by mouth, most of a dose is destroyed before it reaches the blood: a clinical pharmacology review puts the systemic bioavailability at only around 40%.

What the research says

For the oral route, this is one of the clearest negative evidence bases in over-the-counter medicine. A 2007 systematic review found the 10 mg dose did nothing more than placebo to nasal airway resistance. Two large trials funded in response to FDA requests, one in 539 people at doses up to 40 mg and one in 575 people using a 30 mg modified-release tablet, both found no benefit over placebo. A 2023 systematic review reached the same conclusion. One meta-analysis of the old 1970s studies did find an effect, and that disagreement is set out below. In November 2024 the FDA proposed removing oral phenylephrine from the monograph on effectiveness grounds, stating the proposal is not about safety. The agency's action does not cover phenylephrine nasal sprays, and we found no good evidence either way for the spray.

Evidence grade: Not supported by the research.

How it works

Drug class: Direct-acting alpha1-adrenoceptor agonist, used as a nasal decongestant

Phenylephrine stimulates alpha-1 adrenergic receptors directly, which narrows blood vessels; the prescription injection label calls it an alpha-1 adrenergic receptor agonist and records that most vascular beds are constricted, including renal, splanchnic and hepatic. In the nose that narrowing would shrink the swollen lining and open the airway. The same label records that phenylephrine is extensively metabolised by the liver, with deamination by monoamine oxidase as the main route and only 12% of an injected dose leaving unchanged in the urine. That label describes an injection into a vein and says nothing about a swallowed dose; what happens to a tablet before it reaches the blood is a separate question, answered from a clinical pharmacology review rather than from this label. (Source 1)

What it is used for

• A 2007 systematic review found the 10 mg dose no better than placebo on nasal airway resistance, a 2023 systematic review of four studies agreed, and the FDA proposed removing oral phenylephrine from the monograph in November 2024. One meta-analysis of single-dose studies, identified partly from the 1976 FDA monograph bibliography, disagrees. Evidence: not-supported. (Source 2)
• Two randomised trials found no benefit over placebo: an open-label dose-ranging trial in 539 adults at fixed doses of 10, 20, 30 and 40 mg, and a double-blind trial in 575 adults using a 30 mg modified-release tablet every 12 hours. Neither abstract claims the trial was adequately powered and neither sets an equivalence margin, so these are null results rather than demonstrated equivalence. Evidence: not-supported. (Source 3)
• A different route with a separate evidence base. FDA states its 2024 proposal covers only the oral form, and we found no systematic review of the phenylephrine spray. Evidence: unknown. (Source 4)

Interactions

• Monoamine oxidase inhibitors (MAOIs), including certain antidepressant, psychiatric and Parkinson's disease medicines (label): The US label treats this as an absolute contraindication rather than a caution, and extends it for two weeks after the MAOI is stopped. (Source 5)
• Moclobemide, a reversible MAO-A inhibitor (clinical trial): The blanket MAOI warning may not apply equally to the newer reversible inhibitors. A review of moclobemide interaction studies in healthy subjects and patients reported only a negligible interaction with phenylephrine. That is a single review of one drug, and it does not transfer to the older irreversible MAOIs. (Source 6)
• Bitter orange extract and p-synephrine, sold in weight-loss and pre-workout supplements (theoretical): We found no study of phenylephrine with any dietary supplement. The nearest evidence concerns p-synephrine, a structurally related sympathomimetic sold in supplements, which raised both systolic and diastolic blood pressure in pooled placebo-controlled trials after prolonged use. This is about a different molecule, so treat it as a reason for caution rather than as a measured interaction. (Source 7)
• Existing heart disease, high blood pressure, thyroid disease, diabetes or prostate enlargement (label): The label does not forbid use in these conditions but tells people to consult a doctor first, which is a caution carried over from the sympathomimetic class rather than from trials of this drug. (Source 5)

Stopping it

• No withdrawal syndrome, rebound effect or taper is described in the literature we searched for oral phenylephrine. The label sets a time limit instead, directing people to stop and ask a doctor if symptoms have not improved within 7 days or come with a fever. (Source 5)
• Anyone deciding whether to keep taking it should know what the regulator's concern actually is. FDA states its 2024 proposal to remove oral phenylephrine rests on effectiveness, not on safety, and that products may still be sold until a final order issues. (Source 4)

What goes wrong

In the open-label dose-ranging trial, 18.4% of participants reported at least one adverse event while on treatment, most often headache, with no placebo comparison printed. (Source 8)

• Randomized trial, Low certainty.
• Size: 539 adults; the abstract gives one pooled rate across all arms.
• Who: adults with seasonal allergic rhinitis.
• How long: 7 days.
• Result: at least 1 treatment-emergent adverse event in 18.4% of participants; most common headache 3.0%; the abstract reports no separate placebo-arm rate, and the trial was open-label.
• Funding: not stated.

PE HCl was well tolerated at doses of up to 30 mg. At least 1 treatment-emergent adverse event was experienced by 18.4% of the participants, the most common being headache (3.0%).

What the evidence supports

One meta-analysis of pooled single-dose studies did find a single 10 mg oral dose better than placebo on nasal airway resistance. (Source 9)

• Meta-analysis, Low certainty.
• Size: 113 subjects pooled from 7 crossover studies, plus a 50-subject parallel-group trial reanalysed but not pooled.
• Who: adults with acute nasal congestion from a cold.
• How long: single dose, measured to 180 minutes.
• Result: significant difference favouring phenylephrine at 30, 60 and 90 minutes in both fixed- and random-effects models (P <or= 0.05); reductions in nasal airway resistance from baseline ranged 6.0 to 16.6 percentage points greater than placebo between 30 and 90 minutes; significant in only 4 of the 8 individual studies.
• Funding: not stated in the abstract.

Phenylephrine 10 mg was significantly more effective than placebo at the primary time points and at 90 minutes after dosing in the meta-analyses using both the fixed-effects and random-effects models (P <or= 0.05).

That meta-analysis concluded a single 10 mg oral dose is effective in colds. (Source 10)

• Meta-analysis, Low certainty.
• Size: 7 crossover studies plus one reanalysed parallel-group study.
• Who: adults with acute nasal congestion associated with the common cold.
• How long: single dose.
• Result: the authors state the pooled results support effectiveness; nasal airway resistance, not symptoms, was the endpoint.
• Funding: not stated in the abstract.

These meta-analyses of 7 crossover studies and the reanalysis of a parallel-group study support the effectiveness of a single oral dose of phenylephrine 10 mg as a decongestant in adults with acute nasal congestion associated with the common cold.

What the evidence does not support

Pooled unpublished trials found 10 mg of oral phenylephrine did no more for nasal airway resistance than placebo. (Source 2)

• Meta-analysis, Low certainty.
• Size: 138 patients across 8 unpublished studies for the 10 mg dose; 8 further unpublished studies for 25 mg.
• Who: patients with nasal congestion.
• How long: single-dose laboratory measurement of nasal airway resistance.
• Result: mean maximal difference in relative change from baseline between phenylephrine 10 mg and placebo 10.1% (95% CI -3.8% to 23.9%), so the interval crosses zero; 25 mg reduced maximal resistance by 27.6% (95% CI 17.5% to 37.7%) but with significant heterogeneity.
• Funding: independent of the manufacturers; the authors note the pooled studies were unpublished.

Based on 8 unpublished studies that included 138 patients, phenylephrine 10 mg did not affect NAR more than placebo; the mean maximal difference in relative change from baseline between phenylephrine and placebo was 10.1% (95% CI -3.8% to 23.9%). Eight unpublished studies on phenylephrine 25 mg showed a significant reduction of maximal NAR compared with placebo of 27.6% (95% CI 17.5% to 37.7%). There was significant heterogeneity among the studies included in this analysis, which was partially attributable to different laboratories and methods used.

The same review concluded there is not enough evidence that the over-the-counter dose of oral phenylephrine works as a decongestant. (Source 11)

• Systematic review, Low certainty.
• Size: 8 unpublished studies in 138 patients for the 10 mg analysis and eight unpublished studies for 25 mg; the review states no combined total and does not say the two sets are separate.
• Who: patients with nasal congestion.
• How long: single dose.
• Result: no effective dose was established at non-prescription strength; the authors called on the FDA to require further studies.
• Funding: independent.

There is insufficient evidence that oral phenylephrine is effective for nonprescription use as a decongestant. The Food and Drug Administration should require additional studies to show the safety and efficacy of phenylephrine.

A 539-person randomised trial found no dose of oral phenylephrine from 10 mg up to 40 mg beat placebo for congestion in hay fever. (Source 8)

• Randomized trial, Moderate certainty.
• Size: 539 adults randomised to fixed doses of 10, 20, 30 or 40 mg of phenylephrine or placebo.
• Who: otherwise healthy adults with seasonal allergic rhinitis.
• How long: 7 days of treatment.
• Result: none of the phenylephrine groups differed significantly from placebo on instantaneous or reflective nasal congestion scores; the trial was open-label, which the authors state.
• Funding: not stated in the abstract.

None of the PE HCl treatment groups had a statistically significant change from baseline in instantaneous or reflective nasal congestion scores compared with the placebo group.

A 575-person double-blind randomised trial of a 30 mg modified-release phenylephrine tablet found no benefit over placebo. (Source 12)

• Randomized trial, Moderate certainty.
• Size: 575 patients; 288 on modified-release phenylephrine and 287 on placebo.
• Who: adults at least 18 years old with documented hypersensitivity to fall pollen allergens.
• How long: every 12 hours for 7 days, 30 August to 12 October 2011.
• Result: primary endpoint change in daily reflective nasal congestion score: phenylephrine mean -0.394 (SD 0.4880) versus placebo mean -0.412 (SD 0.5383), P = .2655; most secondary endpoints and quality of life also showed no difference.
• Funding: not stated; registered as NCT01413958 after an FDA recommendation.

No significant beneficial difference was detected between PEH-MR and placebo for the primary end point (PEH-MR, mean -0.394, SD 0.4880; placebo, mean -0.412, SD 0.5383; P = .2655).

A 2023 systematic review of four studies found oral phenylephrine was consistently no better than placebo for nasal congestion in adults. (Source 13)

• Systematic review, Low certainty.
• Size: 4 articles met the inclusion criteria.
• Who: adults with nasal congestion.
• How long: trials published between 1998 and 2023.
• Result: the review reports no quantitative pooling; the finding across the four studies was that phenylephrine was not more effective than placebo, and that side effects were headaches and mild discomfort with no life-threatening events.
• Funding: not stated.

The findings consistently indicated that phenylephrine was not more effective than a placebo in relieving nasal congestion. This systematic review demonstrates that oral phenylephrine did not offer substantial relief from nasal congestion compared to a placebo in adults. The studies featured diverse designs, yet the prevailing conclusion was that phenylephrine's efficacy was limited.

A clinical pharmacology review argued phenylephrine is a poor oral substitute for pseudoephedrine because the gut destroys most of it. (Source 14)

• Expert review, not systematic, Low certainty.
• Size: not stated; a literature search of electronic databases and textbooks.
• Who: people using over-the-counter cold and cough medicines.
• How long: not applicable.
• Result: no effect size; the review states phenylephrine is extensively metabolised in the gut and its decongestant efficacy is unproven, while pseudoephedrine's is supported by clinical trials.
• Funding: not stated.

PE is a poor substitute for PDE as an orally administered decongestant as it is extensively metabolized in the gut and its efficacy as a decongestant is unproven. Both PDE and PE have a good safety record, but the efficacy of PDE as a nasal decongestant is supported by clinical trials.

The FDA's position, dated 7 November 2024, is that oral phenylephrine is not effective as a nasal decongestant, and that its advisory committee was unanimous. (Source 4)

• Official position, Certainty not rated.
• Size: not applicable.
• Who: US over-the-counter monograph drug products.
• How long: the agency reviewed data from the 1970s monograph onwards.
• Result: a proposed order, not a final one; FDA states the proposal rests on effectiveness, not safety, and that the Nonprescription Drug Advisory Committee concluded unanimously that current data do not support the monograph dose's effectiveness.
• Funding: not applicable (regulator)

The committee discussed new data on the effectiveness of orally administered phenylephrine and unanimously concluded that the current scientific data do not support that the recommended dosage in the OTC cold, cough, allergy, bronchodilator and antiasthmatic drug products monograph for orally administered phenylephrine’s effectiveness as a nasal decongestant.

The agency's own proposed order is limited to the oral route and does not touch phenylephrine nasal sprays. (Source 15)

• Official position, Certainty not rated.
• Size: not applicable.
• Who: US over-the-counter monograph drug products.
• How long: published 8 November 2024 at 89 FR 88787.
• Result: the order would remove orally administered phenylephrine hydrochloride and phenylephrine bitartrate in an effervescent dosage as nasal decongestant active ingredients.
• Funding: not applicable (regulator)

to remove orally administered phenylephrine hydrochloride and phenylephrine bitartrate in an effervescent dosage as nasal decongestant active ingredients because they are not effective.

A review of interaction studies with the reversible MAO inhibitor moclobemide found only a negligible interaction with phenylephrine. (Source 6)

• Expert review, not systematic, Low certainty.
• Size: not stated; studies in healthy subjects and depressed patients.
• Who: healthy volunteers and patients taking moclobemide.
• How long: short interaction studies.
• Result: no numbers given; moclobemide did not interact with norepinephrine or isoproterenol and interacted with phenylephrine only to a negligible extent. This concerns a reversible MAO-A inhibitor, not the older irreversible MAOIs the label warns about.
• Funding: not stated; published in a supplement reviewing one manufacturer's drug.

Moclobemide did not interact with the direct-interacting sympathomimetics norepinephrine and isoproterenol and only to a negligible extent with phenylephrine.

A clinical pharmacology review puts the systemic bioavailability of swallowed phenylephrine at only around 40%, because monoamine oxidase in the gut wall destroys most of a dose before it reaches the blood. (Source 16)

• Expert review, not systematic, Low certainty.
• Size: not stated; a literature search of electronic databases and textbooks.
• Who: not applicable; a pharmacology comparison of oral phenylephrine and pseudoephedrine.
• How long: not applicable.
• Result: systemic bioavailability of oral phenylephrine around 40% with only about 3% of a dose excreted unchanged in urine, against 43% to 96% excreted unchanged for pseudoephedrine, which resists monoamine oxidase; the review also puts the oral threshold dose for any cardiovascular effect at about 50 mg.
• Funding: no funding source is stated; the paper's conflict-of-interest statement declares that the sole author has acted in the past as a consultant to pharmaceutical companies that market nasal decongestants (Procter & Gamble, GlaxoSmithKline, Pfizer, Reckitt Benckiser, Boots Health Care and Bayer)

The main difference between the decongestants is that after oral administration PE is subject to extensive presystemic metabolism by monoamine oxidase in the gut wall. As a consequence of metabolism, systemic bioavailability of PE is only around 40%. Only about 3% of an oral dose of PE is excreted unchanged in the urine.

Where the evidence is mixed

In the double-blind modified-release trial, adverse events were equally common on drug and on placebo. (Source 12)

• Randomized trial, Moderate certainty.
• Size: 575 patients; 89 had at least one treatment-emergent adverse event.
• Who: adults with allergic rhinitis.
• How long: 7 days.
• Result: 89 of 575 patients (15.5%), equally distributed between the phenylephrine and placebo groups.
• Funding: not stated.

Overall, 89 of 575 patients (15.5%), equally distributed between the PEH-MR and placebo groups, experienced at least 1 treatment-emergency adverse event.

A crossover pharmacokinetic study showed blood levels rise more than proportionally with dose, while pulse and blood pressure fluctuated much as they did on placebo over 12 hours, with extra variability in systolic pressure in the first 2 hours that the paper attributes mainly to the placebo arm. (Source 17)

• Blood level study, Moderate certainty.
• Size: 28 adults enrolled in a four-treatment crossover.
• Who: healthy volunteers housed for 6 days for time-matched measurements.
• How long: single doses of 10, 20 and 30 mg, with 12 hours of monitoring.
• Result: mean Cmax 1354 (SD 954), 2959 (SD 2122) and 4492 (SD 1978) pg/mL for 10, 20 and 30 mg; AUC to infinity 955.8 (SD 278.5), 2346 (SD 983.8) and 3900 (SD 1764) pg·h/mL; both rose disproportionally with dose; negligible phenylephrine and phenylephrine glucuronide in urine; pulse and blood pressure showed similar fluctuations to placebo over 12 hours, although the authors note small differences in systolic pressure during the initial 2 hours; 8 subjects reported 9 mild adverse events, 1 treatment related.
• Funding: industry-funded: the study was sponsored and funded by McNeil Consumer Healthcare, a Division of Johnson & Johnson Consumer, Inc., which makes the Sudafed PE tablet the placebo was matched to, editorial support was also funded by McNeil, and both authors were Johnson & Johnson employees at the time who hold stock or stock options in Johnson & Johnson.

Limit of this finding: Read from the abstract alone, the phrase about small differences in systolic pressure during the initial 2 hours sounds like a difference caused by the drug. The paper’s own full text points the other way: it says the greater variability over the first 2 hours was across assessments and treatments and came mainly from changes in systolic blood pressure from baseline in the placebo group. Nothing here shows phenylephrine raising systolic pressure in the first 2 hours. The study was also run and paid for by the manufacturer of the comparator tablet, and both authors were its employees with stock in the company, so its safety reassurance is not independent.

After oral administration, phenylephrine was rapidly absorbed with median times to maximum plasma concentrations (t max) from 0.33 to 0.5 h. For phenylephrine HCl 10, 20, and 30 mg, the mean (standard deviation) maximum concentration (C max) was 1354 (954), 2959 (2122), and 4492 (1978) pg/mL, and total systemic exposure [area under the plasma concentration-time curve from time zero to infinity (AUC∞)] was 955.8 (278.5), 2346 (983.8), and 3900 (1764) pg·h/mL, respectively. Both parameters increased disproportionally with increasing dose, as β >1 in the power model. Negligible amounts of phenylephrine and phenylephrine glucuronide were excreted in urine.

The published paper reports that 28 volunteers enrolled in the pharmacokinetic study but only 27 completed all four treatments. (Source 18)

• Blood level study, Moderate certainty.
• Size: 28 enrolled, 27 completing all four treatments; data from all 28 were analysed.
• Who: healthy adults, mean age 32.0 years, mean weight 70.0 kg; four Asian, four black, 11 Hispanic and nine white subjects.
• How long: four single-dose treatments on consecutive days, housed for 6 days.
• Result: one subject withdrew for personal reasons after two treatments and part of a third; the paper states that the available pharmacokinetic, safety and cardiovascular data for all 28 subjects were included in the analyses, so 28 is the number enrolled and analysed rather than the number who received every dose.
• Funding: industry-funded: the study was sponsored and funded by McNeil Consumer Healthcare, a Division of Johnson & Johnson Consumer, Inc., which makes the Sudafed PE tablet the placebo was matched to, editorial support was also funded by McNeil, and both authors were Johnson & Johnson employees at the time who hold stock or stock options in Johnson & Johnson.

Twenty-eight subjects (13 male and 15 female) enrolled in the study, of whom 27 subjects completed four treatments. One subject withdrew for personal reasons after completing two treatments and partially completing the third.

Where the research disagrees

Whether a single 10 mg oral dose of phenylephrine opens the nose at all

• Hatton and colleagues, Annals of Pharmacotherapy (2007), systematic review with a random-effects meta-analysis; the 10 mg analysis pooled 8 unpublished studies in 138 patients and a separate analysis pooled eight unpublished studies of 25 mg, with no combined total stated and significant heterogeneity between laboratories and methods: They found 10 mg did not affect nasal airway resistance more than placebo, and concluded the evidence for non-prescription use is insufficient. (Source 2)
• Kollar and colleagues, Clinical Therapeutics (2007), reanalysis of individual studies plus fixed-effects and random-effects meta-analysis of 7 crossover studies (113 subjects), with significance in only 4 of the 8 individual studies: They found 10 mg significantly more effective than placebo at 30, 60 and 90 minutes, and concluded the data support effectiveness. (Source 9)
• US Food and Drug Administration, position dated 7 November 2024, regulatory review of the historical monograph data plus newer clinical trials; a proposed order, not a final one: The agency proposes removal because oral phenylephrine is not effective, and reports its advisory committee concluded unanimously that current data do not support the monograph dose. (Source 4)
• Meltzer and colleagues (2015 and 2016), one open-label randomised dose-ranging trial, which the authors say the FDA recommended, and one double-blind placebo-controlled trial of a single modified-release dose: Two trials, in 539 and 575 adults, found no benefit over placebo: the first at fixed doses of 10 to 40 mg, the second at a single 30 mg modified-release dose every 12 hours. (Source 12)

How much

• Reference intake: No reference intake exists, because this is a medicine and not a nutrient. As a dated position, the Kenvue Sudafed PE Sinus Congestion US Drug Facts label published 11 November 2024 gives, for adults and children 12 years and over, a dose of 1 tablet every 4 hours, and directs children under 12 to a doctor. (Source 19)
• Upper limit: No tolerable upper intake level exists. As a dated position, the same Sudafed PE Sinus Congestion US label published 11 November 2024 sets a ceiling of no more than 6 tablets in 24 hours. (Source 19)
• Studied: The dose-ranging trial gave 539 adults fixed doses of 10, 20, 30 or 40 mg of immediate-release phenylephrine, or placebo, for 7 days. (Source 3)
• Studied: The double-blind trial gave 288 adults a 30 mg modified-release tablet every 12 hours for 7 days against 287 on placebo. (Source 20)
• Studied: The pharmacokinetic study enrolled 28 healthy adults for single oral doses of 10, 20 or 30 mg, or placebo, in a four-treatment crossover; 28 is the number enrolled and analysed, and the published paper reports that 27 completed all four treatments. (Source 18)
• Studied: The meta-analysis that found an effect pooled single-dose randomised placebo-controlled studies in which phenylephrine 10 mg was the sole active ingredient. (Source 21)

A common belief, and what the research shows

The belief: Phenylephrine is the decongestant in cold medicines, so a cold tablet that contains it will clear a blocked nose.

What the research shows: For the tablet, the weight of evidence is that it does not. A systematic review found the 10 mg dose no better than placebo on instrument measurement, and two trials found no benefit on symptom scores: one in 539 adults at fixed doses of 10 to 40 mg, and one in 575 adults on a 30 mg modified-release tablet every 12 hours. The likely reason is that monoamine oxidase in the gut wall destroys most of a swallowed dose, leaving a systemic bioavailability of around 40%. One meta-analysis of pooled single-dose studies did find an effect, so this is a real scientific disagreement rather than a settled one, but the newer and larger trials are the negative ones. Two things are worth separating: the FDA’s proposed removal is about effectiveness and not safety, and it applies only to the swallowed form, not to phenylephrine nasal sprays. Other active ingredients in the same tablet, such as paracetamol, are unaffected by any of this.

Questions and answers

What is it?

Phenylephrine hydrochloride is a manufactured drug substance used as a nasal decongestant. In a single-ingredient over-the-counter tablet it appears as ‘Phenylephrine HCl 10 mg’ with the stated purpose ‘Nasal decongestant’, for sinus congestion and pressure and for nasal congestion from a cold, hay fever or other upper respiratory allergies. That is what this one label covers; the nasal spray, the eye drops and the hospital injection are separate products with their own labels, cited separately in this entry. (Source 22)

What does it do in the body?

It stimulates alpha-1 adrenergic receptors directly, which narrows blood vessels; in the nose that should shrink the swollen lining. Swallowed, very little of it gets that far. A clinical pharmacology review states it is extensively metabolised in the gut and that its efficacy as a decongestant is unproven, which is the mechanism behind the negative trials. (Source 14)

Is it good or bad for you?

Taken by mouth the evidence says it mostly does nothing, rather than that it does harm. A 2023 systematic review found it no more effective than placebo and reported no life-threatening adverse events, with headaches and mild discomfort as the common side effects. In the 575-person double-blind trial, adverse events occurred in 15.5% of patients and were equally distributed between drug and placebo. The real cost is an ineffective treatment and money spent, not toxicity. (Source 13)

How do you get more of it?

It is bought over the counter, and it is in a very large number of products. The question is more usefully reversed: since the oral form appears not to work, there is no evidential reason to seek more of it. FDA notes that in multi-ingredient products the presence of oral phenylephrine does not affect how the other active ingredients work. (Source 4)

If it is harmful, what reduces it?

Nothing special is needed. The crossover pharmacokinetic study found it absorbed quickly, with peak blood levels reached about 20 to 30 minutes after a dose, and only negligible amounts of unchanged drug and its glucuronide appearing in urine, the rest having already been converted to other metabolites. The abstract reports no half-life or clearance figure. Stopping the tablet is the whole of it. (Source 17)

Why might someone be low in it or missing it?

The question does not apply: the body neither makes nor needs phenylephrine, so no one can be low in it. If a familiar product no longer contains it, that is regulatory. FDA proposed in November 2024 to remove oral phenylephrine as a monograph decongestant, and said it would give manufacturers time either to reformulate or to withdraw such products. (Source 4)

Which whole foods contain it or feed it?

No food contains phenylephrine in any relevant amount, and we found no study of a food or diet source of it. It is a manufactured drug substance supplied in tablets, liquids, sprays and injections rather than something obtained from food. (Source 14)

We searched: Searched Europe PMC for phenylephrine with food, dietary and natural-occurrence terms, and for food interaction studies; nothing describing a dietary source of phenylephrine was found. The closest relevant literature concerns its destruction in the gut after swallowing.

What happens if you do not have it?

Nothing happens that would not have happened anyway, which is the point of the negative trials. In the 575-person double-blind trial the change in daily reflective nasal congestion score was essentially identical on the 30 mg modified-release tablet and on placebo, -0.394 against -0.412, P = .2655. Congestion from a cold or from hay fever follows its own course either way. (Source 12)

How can you test for it?

There is no test a member can use. Phenylephrine and its metabolites can be measured in blood and urine in research settings, but no clinical test tells anyone whether they need it or whether it is working, and no deficiency state exists to test for. (Source 17)

We searched: Searched Europe PMC for phenylephrine with pharmacokinetics, bioavailability, urine and assay terms. The available human work measures plasma and urinary concentrations and metabolites for research purposes; the 2015 study found negligible unchanged drug in urine. No diagnostic or monitoring test was found.

References

1. DailyMed / US National Library of Medicine (labeler Fresenius Kabi USA, LLC). PHENYLEPHRINE HYDROCHLORIDE injection - US prescribing information, 12 CLINICAL PHARMACOLOGY (12.1 Mechanism of Action, 12.2 Pharmacodynamics, 12.3 Pharmacokinetics). 2026. Read the source
2. The Annals of pharmacotherapy. Efficacy and safety of oral phenylephrine: systematic review and meta-analysis. (abstract: Results). 2007. PMID 17264159, DOI 10.1345/aph.1h679. Read the source
3. The journal of allergy and clinical immunology. In practice. Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study. (abstract: Methods). 2015. PMID 26143019, DOI 10.1016/j.jaip.2015.05.007. Read the source
4. US Food and Drug Administration. FDA Proposes Ending Use of Oral Phenylephrine as OTC Monograph Nasal Decongestant Active Ingredient After Extensive Review - FDA News Release dated November 07, 2024, complete body text. 2024. Read the source
5. Kenvue Brands LLC (US prescribing information via DailyMed, National Library of Medicine). SUDAFED PE SINUS CONGESTION (phenylephrine hydrochloride) tablet, film coated - US Drug Facts label, complete Warnings section. 2024. Read the source
6. Acta psychiatrica Scandinavica. Supplementum. Interaction studies with moclobemide. (abstract). 1990. PMID 2248085, DOI 10.1111/j.1600-0447.1990.tb05343.x. Read the source
7. Nutrients. The Safety and Efficacy of Citrus aurantium (Bitter Orange) Extracts and p-Synephrine: A Systematic Review and Meta-Analysis. (abstract). 2022. PMID 36235672, DOI 10.3390/nu14194019. Read the source
8. The journal of allergy and clinical immunology. In practice. Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study. (abstract: Results). 2015. PMID 26143019, DOI 10.1016/j.jaip.2015.05.007. Read the source
9. Clinical therapeutics. Meta-analysis of the efficacy of a single dose of phenylephrine 10 mg compared with placebo in adults with acute nasal congestion due to the common cold. (abstract: Results). 2007. PMID 17692721, DOI 10.1016/j.clinthera.2007.05.021. Read the source
10. Clinical therapeutics. Meta-analysis of the efficacy of a single dose of phenylephrine 10 mg compared with placebo in adults with acute nasal congestion due to the common cold. (abstract: Conclusion). 2007. PMID 17692721, DOI 10.1016/j.clinthera.2007.05.021. Read the source
11. The Annals of pharmacotherapy. Efficacy and safety of oral phenylephrine: systematic review and meta-analysis. (abstract: Conclusions). 2007. PMID 17264159, DOI 10.1345/aph.1h679. Read the source
12. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. Phenylephrine hydrochloride modified-release tablets for nasal congestion: a randomized, placebo-controlled trial in allergic rhinitis patients. (abstract: Results). 2016. PMID 26560899, DOI 10.1016/j.anai.2015.10.022. Read the source
13. Cureus. The Use and Efficacy of Oral Phenylephrine Versus Placebo Treating Nasal Congestion Over the Years on Adults: A Systematic Review. (abstract). 2023. PMID 38125218, DOI 10.7759/cureus.49074. Read the source
14. British journal of clinical pharmacology. Substitution of phenylephrine for pseudoephedrine as a nasal decongeststant. An illogical way to control methamphetamine abuse. (abstract). 2007. PMID 17116124, DOI 10.1111/j.1365-2125.2006.02833.x. Read the source
15. Food and Drug Administration / Federal Register. Amending Over-the-Counter Monograph M012: Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products for Over-the-Counter Human Use (proposed order, 89 FR 88787, published 2024-11-08) - document Summary. 2024. Read the source
16. British Journal of Clinical Pharmacology. Substitution of phenylephrine for pseudoephedrine as a nasal decongeststant. An illogical way to control methamphetamine abuse. (full text: Pharmacology and metabolism paragraph). 2007. PMID 17116124, DOI 10.1111/j.1365-2125.2006.02833.x. Read the source
17. Clinical drug investigation. Pharmacokinetics, safety, and cardiovascular tolerability of phenylephrine HCl 10, 20, and 30 mg after a single oral administration in healthy volunteers. (abstract: Results). 2015. PMID 26267590, DOI 10.1007/s40261-015-0311-9. Read the source
18. Clinical Drug Investigation. Pharmacokinetics, safety, and cardiovascular tolerability of phenylephrine HCl 10, 20, and 30 mg after a single oral administration in healthy volunteers. (full text: Results, Subjects paragraph). 2015. PMID 26267590, DOI 10.1007/s40261-015-0311-9. Read the source
19. Kenvue Brands LLC (US over-the-counter Drug Facts label via DailyMed, National Library of Medicine). SUDAFED PE SINUS CONGESTION (phenylephrine hydrochloride) tablet, film coated - US Drug Facts label, Directions section (a two-column, two-row table; each row is a label line followed by its value lines, and the blank line is the row boundary). 2024. Read the source
20. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. Phenylephrine hydrochloride modified-release tablets for nasal congestion: a randomized, placebo-controlled trial in allergic rhinitis patients. (abstract: Methods). 2016. PMID 26560899, DOI 10.1016/j.anai.2015.10.022. Read the source
21. Clinical therapeutics. Meta-analysis of the efficacy of a single dose of phenylephrine 10 mg compared with placebo in adults with acute nasal congestion due to the common cold. (abstract: Methods). 2007. PMID 17692721, DOI 10.1016/j.clinthera.2007.05.021. Read the source
22. Kenvue Brands LLC (US prescribing information via DailyMed, National Library of Medicine). SUDAFED PE SINUS CONGESTION (phenylephrine hydrochloride) tablet, film coated - US Drug Facts label, Active ingredient, Purpose and Uses sections. 2024. Read the source